Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Other Accumulated Expenses (2016 - 2024)

Historic Other Accumulated Expenses for Voyager Therapeutics (VYGR) over the last 10 years, with Q3 2024 value amounting to $7.0 million.

  • Voyager Therapeutics' Other Accumulated Expenses rose 12469.41% to $7.0 million in Q3 2024 from the same period last year, while for Sep 2024 it was $7.0 million, marking a year-over-year increase of 12469.41%. This contributed to the annual value of $3.2 million for FY2023, which is 1299.44% up from last year.
  • As of Q3 2024, Voyager Therapeutics' Other Accumulated Expenses stood at $7.0 million, which was up 12469.41% from $6.7 million recorded in Q2 2024.
  • Voyager Therapeutics' Other Accumulated Expenses' 5-year high stood at $7.0 million during Q3 2024, with a 5-year trough of $2.5 million in Q2 2022.
  • Its 5-year average for Other Accumulated Expenses is $4.2 million, with a median of $3.5 million in 2020.
  • As far as peak fluctuations go, Voyager Therapeutics' Other Accumulated Expenses plummeted by 4916.53% in 2022, and later skyrocketed by 12469.41% in 2024.
  • Voyager Therapeutics' Other Accumulated Expenses (Quarter) stood at $4.2 million in 2020, then soared by 32.71% to $5.6 million in 2021, then tumbled by 49.17% to $2.8 million in 2022, then grew by 12.99% to $3.2 million in 2023, then soared by 118.09% to $7.0 million in 2024.
  • Its Other Accumulated Expenses stands at $7.0 million for Q3 2024, versus $6.7 million for Q2 2024 and $5.9 million for Q1 2024.